51st Annual Meeting & ToxExpo - Society of Toxicology

Society of Toxicology 2012
Scientific
Workshops
The Thematic Track information can be found on pages 8–9.
models. We will then turn our attention to the US EPA and industry
perspectives, focusing on pathway prediction and next generation
coculture models. The final overview will provide a platform to
discuss the bioinformatic tools to mine databases used to predict drug
hepatotoxicity from the perspective of the US FDA. At the conclusion
of this session, our panel of experts will engage participants in an
interactive discussion about the topic. The diversity of speakers will
allow perspectives from a number of groups whose work is driven by
various regulatory pressures. This session is sure to be of interest to
those interested in high-throughput screening, hepatotoxicity, toxicogenomics,
and mode of action research.
• From Primary Cells to Human Stem Cell-Derived Models:
Towards More Predictive In Vitro Models of Liver Toxicity.
Stefan Mueller, Merck, Darmstadt, Germany.
• Interindividual Variability in Genomic Responses in Human
Primary Hepatocytes and Comparison with Human Cell Lines.
Joost van Delft, Maastricht University, Maastricht, Netherlands.
• Genetic Identification of Pathway Signatures and Assessment of
Effects in Mouse and Human In Vitro Liver Models. Chris Corton,
US EPA, Research Triangle Park, NC.
• Prediction of Complex Toxicities Using 3D Liver Coculture and
Toxicogenomics. Dawn Applegate, RegeneMed, San Diego, CA.
• Translational Biomarkers for Drug-Induced Liver Injury.
Weida Tong, US FDA, Jefferson, AR.
Clinical Toxicology from Bedside to the
Bench and Back
Nonclinical and Clinical Applications of
Translational Organ-Based Imaging
Tuesday, March 13, 1:30 PM to 4:15 PM
Chairperson(s): Syril Pettit, HESI, Washington, DC, and Norman
Barlow, sanofi-aventis, Bridgewater, NJ.
Sponsor:
Toxicologic and Exploratory Pathology Specialty Section
Endorsed by:
Cardiovascular Toxicology Specialty Section
Comparative and Veterinary Specialty Section
Drug Discovery Toxicology Specialty Section
Neurotoxicology Specialty Section
Reproductive and Developmental Toxicology Specialty Section
Multimodal imaging is a widely applied and accepted standard of
care in many medical settings. Innovations in imaging capabilities
have developed rapidly, allowing noninvasive collection of an ever
increasing quantity and quality of morphologic, functional, and even
molecular data from humans and animals. Accordingly, imaging
is becoming an important component of the clinical biomarker
toolbox. However, advances in imaging strategies that have allowed
for use in animals, including rodents, have not driven a large-scale
integration of these capabilities into modern toxicology assessment or
environmental hazard identification. Although a number of imaging
and biomarker “opportunities” are outlined in the FDA’s “Critical
Path Opportunities List,” an organized effort to explore integration
of imaging into nonclinical safety assessment and hazard evaluation
paradigms is just beginning. We will provide an overview of an
organ-based approach to novel imaging methodologies in nonclinical
safety assessment and translational toxicology. The presentations will
describe how preclinical imaging can be an innovative tool for toxicity
assessment, and how translational imaging can be used to bridge the
gap between nonclinical safety assessment and clinical testing.
• Cardiovascular Imaging in Nonclinical Safety Studies: Increasing
Acceptance and Application. Robert Coatney, GlaxoSmithKline,
King of Prussia, PA.
• Multimodal Imaging in Developmental and Reproductive
Toxicology. Xiaoyou Ying, sanofi-aventis US, Bridgewater, NJ.
• Preclinical Assessment of Neurotoxicity with Imaging.
William Slikker Jr., US FDA, Jefferson, AR.
• Imaging the Liver and Heart: MRI Applications. Paul Hockings,
AstraZeneca, Mölndal, Sweden.
• Lessons Learned from Lung Imaging in Multicenter Studies.
Eric Hoffman, University of Iowa Carver College of Medicine,
Iowa City, IA.
Characterizing Toxic Modes of Action
and Pathways to Toxicity
Novel Topics in Environmental Polycyclic
Aromatic Hydrocarbon Metabolism Leading to
Carcinogenesis
Tuesday, March 13, 1:30 PM to 4:15 PM
Chairperson(s): Danielle Carlin, NIEHS, Durham, NC, and
Bhagavatula Moorthy, Baylor College of Medicine, Houston, TX.
Sponsor:
Carcinogenesis Specialty Section
Endorsed by:
Mechanisms Specialty Section
Mixtures Specialty Section
Risk Assessment Specialty Section
Epidemiological evidence indicates that exposure to complex
environmental polycyclic aromatic hydrocarbon (PAH) mixtures
increases the risk of lung cancer. However, most animal studies
have focused on single PAH components. Moreover, little is known
regarding the interactions between different PAH metabolites
that lead to carcinogenesis. Thus, our panel of experts will provide
Thematic Session
92
SOT’s 51 st Annual Meeting